Straits Times Index
3,363.68 -13.97 (-0.41%) S&P 500
4,156.57 +37.36 (+0.91%) Dow
33,922.78 -170.18 (-0.50%) Nasdaq
12,078.25 +261.93 (+2.22%) BTC-USD
23,602.06 +517.32 (+2.24%) CMC Crypto 200
539.14 -6.17 (-1.13%)
AstraZeneca PLC (AZN)
- Business Wire
TEZSPIRE® approved for self-administration in the US with a new pre-filled pen
WILMINGTON, Del., February 02, 2023--AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation within its approved label.1
- Zacks
Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints
Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.
- Motley Fool
3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023
Top dividend stocks are capable of delivering above-average returns returns in any type of market. Which dividend stocks are no-brainer buys for retail investors right now? AstraZeneca (NASDAQ: AZN), Merck (NYSE: MRK), and Medtronic (NYSE: MDT) are three elite income stocks that have recession-proof businesses, strong growth prospects, and ample free cash flows.
